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1.  Advances in our knowledge of cytogenetic abnormalities and 
gene mutations
Myelodysplastic syndromes (MDS) constitute a group of age-associated hetero-
geneous clonal hematopoietic disorders characterized by ineffective hematopoiesis 
with peripheral cytopenias, dysplasia, and an increased risk of progression to acute 
myeloid leukemia (AML) [1–6]. About 50% of cases of MDS are characterized 
by the presence of cytogenetic abnormalities. Losses of chromosomal material as 
del(5q), del(20q), monosomy 7 or del(7q), and del(Y) are most common cytoge-
netic abnormalities and are more frequent than gains of chromosomal material as 
trisomy 8 or trisomy 21 [7].
MDS are caused by abnormalities in many genes. The great progress in analysis 
of these mutations and in elucidation of relationships between gene mutations 
and clinical phenotypes of these disorders was achieved. Somatic mutations were 
found in more than 90%. Next-generation sequencing (NGS) detected about 
10 different mutations in almost every patient with MDS. The majority of these 
mutations are nonpathogenic passenger mutations. However, one or more driver 
mutations in most patients with MDS are associated with the pathogenesis of 
MDS. Gene mutations affect proteins involved in various important cell processes 
as RNA-splicing, DNA methylation, histone and chromatin modifications, signal 
transduction, transcription (transcription factors), tumor suppressor (TP53), 
RAS pathway, and separation of sister chromatids during cell division (cohesion 
complex) [4, 8–10].
RNA-splicing and DNA methylation mutations occur early and are known as 
founding mutations. Other mutations are called subclonal mutations. No MDS-
specific mutations exist. Strongly represented mutations in genes coding for 
proteins involved in DNA methylation, such as TET2, DNMT3A, and ASXL1, are 
common also in older individuals with normal blood count (clonal hematopoiesis 
of indeterminate potential/CHIP/) [11, 12]. Until now, mutations in TP53, EZH2, 
RUNX1, and SF3B1 predict independently overall survival (OS) of MDS patients. 
The first three mutations are associated with shorter OS but the last mutation 
is connected with better survival in refractory anemia with ring sideroblast 
(MDS-RS) and with thrombocytosis (RARS-T) [13, 14]. SF3B1 mutations are pres-
ent in about 80% of MDS-RS and correlates with its development. SF3B1 mutations 
could alter the expression of the gene for ABCB7 transporter and abnormally 
regulate iron homeostasis in mitochondria mediating the phenotype of acquired 
MDS-RS [15]. Effects of other mutations are not clear up to now and results are 
often controversial.
We lack clinical methods to stop clonal development from relatively benign state 
of CHIP to malignancy. Especially, TP53-mutant clones induce progress to therapy-
related MDS/AML. Therapy-related myeloid neoplasms have mutations in TP53 and 
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epigenetic modifying genes, instead of mutations in tyrosine kinase and spliceo-
some genes [16]. The possible treatments are now the use of hypomethylating agents 
or in future anti-inflammatory therapy and clonally selective immunotherapies.
MDS are associated with genomic instability and extensive DNA damage caused 
by deficient repair mechanisms. Aberrations in DNA damage response/repair genes 
other than TP53 and some genes involved in DNA damage checkpoints are rare. 
Differential expression of homologous recombination DNA repair-associated genes 
during MDS progression was detected and could be confirmed as new biomarkers 
related to pathogenesis and poor prognosis in MDS [17, 18].
2.  Advance in our understanding of del(5q) myelodysplastic syndrome 
pathogenesis and its treatment with lenalidomide
The greatest progress was achieved in the study of molecular pathogenesis 
of del(5q) MDS disease phenotype and its treatment by immunomodulatory or 
cereblon-binding drug lenalidomide [2, 19–35]. Ebert et al. described that impaired 
ribosome biosynthesis due to RPS14 (ribosomal protein 14 of the small ribosome 
subunit) gene haploinsufficiency leads to the E3 ubiquitin ligase HDM2 (human 
homolog to mouse double minute 2, major negative regulator of p53) inactivation 
by free ribosomal proteins, particularly RPL11 [36]. HDM2 degradation drives 
p53-mediated apoptosis of erythroid cells carrying the del(5q) aberration. This 
p53-mediated apoptosis of erythroid cells is a key effector of hypoplastic anemia in 
MDS patients with del(5q) [36]. RPS14 haploinsufficiency causes a block in ery-
throid differentiation mediated by calprotectin (the heterodimeric S100 calcium-
binding proteins S100A8 and S100A9) [37]. Proinflammatory proteins, S100A9 and 
tumor necrosis factor-α, suppress the effect of erythropoietin in MDS [38]. Some 
patients originally considered as MDS patients without del(5q) can have a pheno-
type of atypical 5q− syndrome and can be sensitive to lenalidomide therapy because 
they have diminutive somatic deletions in the 5q region. These deletions were not 
identified by fluorescence in situ hybridization or cytogenetic testing but by single 
nucleotide polymorphism array genotyping [39]. Low RPS14 expression in 50–70% 
MDS patients without del(5q) confers higher apoptosis rate of nucleated erythro-
cytes and predicts prolonged survival [40, 41].
What is the mechanism of lenalidomide in del(5q) MDS based on what has been 
achieved and elucidated to date? Lenalidomide stabilizes E3 ubiquitin ligase HDM2, 
thereby accelerating p53 degradation [42, 43]. Lenalidomide inhibits phosphatases 
PP2a and Cdc25c (coregulators of cell cycle which genes are very commonly deleted 
in del(5q) MDS) with consequent G2 arrest of del(5q) MDS progenitors and their 
apoptosis. PP2a and Cdc25c inhibition by lenalidomide suppress HDM2 autoubiq-
uitination and subsequent degradation. Thus, lenalidomide has been shown to not 
only reverse apoptosis within the erythroid compartment, but also directly induce 
apoptosis of the myeloid clone in del(5q) MDS [44, 45]. Lenalidomide upregulates 
expression of other two haploinsufficient genes located on chromosome 5q, genes 
for microRNAs (miR-145 and miR-146a) [46]. These miRs are involved in Toll-like 
receptor pathway, IL-6 induction, and regulation of megakaryopoiesis [20].
Ito et al. discovered that thalidomide (founding member of immunomodulatory 
drugs/IMiDs/) binds cereblon (CRBN) in the terminal C-region (parts of exons 10 
and 11 of the CRBN gene code this IMiD binding region) [47]. Several researchers 
confirmed CRBN as target of lenalidomide in multiple myeloma (MM), lymphoma, 
chronic lymphocytic leukemia, and del(5q) MDS [48]. CRBN is the ubiquitously 
expressed 51 kDa protein with a putative role in cerebral development, especially 
memory and learning [49, 50].
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Our group found that del(5q) MDS patients (the so-called 5q minus syndrome) 
have higher levels of full-length CRBN mRNA than other patients with lower risk 
MDS, linking higher levels of a known lenalidomide target CRBN and del(5q) MDS 
subgroup known to be especially sensitive to lenalidomide [51].
CRBN is a member and substrate receptor of the cullin 4 RING E3 ubiquitin 
ligase complex (CRL4). CRBN recruits substrate proteins to the CRL4 complex 
for ubiquitination and the subsequent degradation in proteasomes. IMiDs binds to 
CRBN in CRL4 complex and block normal endogenous substrates (CRBN and the 
homeobox transcription factor MEIS2 in multiple myeloma/MM/) from binding to 
CRL4 for ubiquitination and degradation [52]. After IMID binding to CRBN, CRL4 
complex is recruiting transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) for 
ubiquitination and degradation in MM cells [53]. Degradation of these transcription 
factors explains lenalidomide’s growth inhibition of MM cells and increased interleu-
kin-2 (IL-2) release from T cells. However, it is unlikely that degradation of IKZF1 
and IKZF3 accounts for lenalidomide’s activity in MDS with del(5q). Fink et al. 
identified a novel target casein kinase1A1 (CSNK1A1) by quantitative proteomics 
in the myeloid cell line KG-1 [54]. CSNK1A1 is encoded in the del(5q) commonly 
deleted region and the gene is haploinsufficient. Lenalidomide treatment leads to 
increased ubiquitination of the remaining CSNK1A1 and decreased protein abun-
dance. CSNK1A1 negatively regulates β-catenin which drives stem cell self-renewal, 
and CSNK1A1 haploinsufficiency causes the initial clonal expansion in patients with 
the del(5q) MDS and contributes to the pathogenesis of del(5q) MDS. The further 
inhibition of CSNK1A1 in del(5q) MDS is associated with del(5q) failure and p53 
activation. The inhibition of CSNK1A1 reduced RPS6 phosphorylation, induced p53 
expression and growth inhibition, and triggered myeloid differentiation program. 
TP53-null leukemia did not respond to CSNK1A1 inhibition, strongly supporting 
the importance of the p53 expression for the yield of CSNK1A1 inhibition. CSNK1A1 
mutations have been recently found in 5–18% of MDS patients with del(5q) [55]. 
These mutations are associated similarly to the effect of TP53 mutations with rise to a 
poor prognosis in del(5q) MDS [56]. Other studies did not find impact of CSNK1A1 
mutations on lenalidomide treatment in del(5q) MDS [57, 58].
Even if the treatment of del(5q) MDS patients with lenalidomide is very effi-
cient, 50% of treated patients relapse after 2–3 years. Martinez-Hoyer et al. found 
that low platelet count and occurrence of additional mutations, mainly TP53 muta-
tions induce lenalidomide resistance [59–61]. They used whole genome sequencing 
and observed in several resistant patients mutations in RUNX1 gene or decreased 
amount of RUNX1 transcript without aberration in TP53 [59]. Results were verified 
in model system of two human del(5q) lines, MDS-L and KG-1a. RUNX1 knock-out 
or RUNX1 shRNA increased proliferation and reduced apoptosis in lenalidomide-
treated cells with decreased RUNX1 transcript. Therefore, effect of lenalidomide 
in del(5q) requires functional RUNX1. Similar results were obtained with TP53 
knock-out cells. Both RUNX1 and TP53 transcripts cooperate and alter the activity 
of GATA2 transcriptional complex [59].
3.  Studies on lenalidomide use also in lower risk non-del(5q) MDS 
treatment and new possible therapies
While CSNK1A1 is CRL4CRBN target in del(5q) MDS, CRL4CRBN targets in 
lower risk non-del(5q) remain to be determined. The mechanism of action of 
lenalidomide is still unclear in non-del(5q) MDS cells. Recent evidence shows that 
lenalidomide directly improves erythropoietin receptor (EPOR) signaling by EPOR 
upregulation mediated by a posttranscriptional mechanism [62]. Lenalidomide 
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stabilizes the EPOR protein by inhibition of the E3 ubiquitin ligase RNF41 (ring 
finger protein 41, also known as neuregulin receptor degradation protein-1/Nrdp1/
and fetal liver ring finger/FLRF/) responsible for EPOR polyubiquitination and 
next degradation [62] and induces lipid raft assembly to enhance EPOR signaling in 
MDS erythroid progenitors [63, 64].
After failure of ESAs, lenalidomide yields red blood cell transfusion indepen-
dence in 20–30% of lower risk non-del(5q) MDS. Indeed, several observations 
suggest an additive effect of ESA and lenalidomide in this situation [65, 66] and 
also in del(5q) MDS patients [67]. Synthetic corticosteroids (dexamethasone and 
prednisone) are also able to potentiate the effect of lenalidomide or combination of 
lenalidomide and erythropoietin [67–69].
Basiorka et al. and Sallman et al. reported activation of the NLRP3 inflamma-
some in MDS [70, 71]. NRLP3 drives clonal expansion and pyroptotic cell death. 
Independent of genotype, MDS hematopoietic stem and progenitor cells (HSPCs) 
overexpress inflammasome proteins. Activated NLRP3 complexes direct then 
activation of caspase-1, generation of interleukin-1β (IL-1β) and IL-18, and pyrop-
totic cell death. Mechanistically, pyroptosis is triggered by the alarmin S100A9 that 
is found in excess in MDS HSPCs and bone marrow plasma. Further, like somatic 
gene mutations, S100A9-induced signaling activates NADPH oxidase (NOX) and 
increasing levels of reactive oxygen species (ROS). ROS initiate cation influx, cell 
swelling, and β-catenin activation. Knockdown of NLRP3 or caspase-1, neutraliza-
tion of S100A9, and pharmacologic inhibition of NLRP3 or NOX suppress pyrop-
tosis, ROS generation, and nuclear β-catenin in MDSs and are sufficient to restore 
effective hematopoiesis. Thus, alarmins and founder gene mutations in MDSs cause 
a common redox-sensitive inflammasome circuit. They are new candidates for 
therapeutic intervention.
Not only apoptosis and pyroptosis are involved in increased cell death in 
MDS. Recently, possible further mechanism of cell death, necroptosis, in MDS 
has been described [72, 73]. Necroptosis is like pyroptosis associated with mem-
brane permeabilization and the release of damage-associated molecular patterns 
(DAMPs) such as alarmins. Alarmins bind Toll-like receptor 4 (TLR4) and activate 
the transcription factor NF-κB and inflammation [74].
The effects of lenalidomide in non-del(5q) are thought to be secondary to 
modulation of the immune system. Hyperactivated T cells inhibit hematopoiesis. 
Immunosuppressive therapies with antithymocyte globulin alone and in combination 
with prednisone or cyclosporine show response rates between 25 and 40% [75, 76].
The studies discussed in this and other chapters of this book will help to trans-
late our knowledge of genetic aberrations and of pathophysiological mechanisms 
in MDS into clinical use in diagnosis, prognosis, and therapy. Novel agents devel-
oped on the basis of this knowledge (luspatercept, rigosertib, immune checkpoint 
inhibitors, venetoclax, and others) are in clinical trials and will help in relapsed/
refractory MDS.
The work of our group in this area was supported by the research project 
for conceptual development of research organization (00023736; Institute of 
Hematology and Blood Transfusion, Prague) from the Ministry of Health of the 
Czech Republic.
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